Summary
The evaluation partially aligns with the FDA label. Many adverse effects and management recommendations are reflected, but there are notable omissions of high-risk warnings (suicidality) and discontinuation guidance that are present in the label.
Category Scores
Accurate Statements
Qelbree (viloxazine) can cause side effects that may be more noticeable when starting treatment or after dose changes.
2.2; 5.1
Qelbree can cause sleep-related issues such as sleepiness.
5.4
Qelbree can affect heart-rate and blood-pressure parameters in some patients.
5.2
Sleep changes often improve after the body adjusts.
5.4
Qelbree can cause weight changes.
8.4
Qelbree can cause nausea.
6
Qelbree can cause vomiting.
6
Some side effects can be serious and require prompt medical attention.
5.1; 6
Some side effects can be serious and require prompt medical attention, especially changes in mood or behavior.
5.1
Dose adjustments may be considered.
2.2
The time of day the medicine is taken may be adjusted, especially for sleep-related effects.
2.3
The titration schedule may be adjusted.
2.2
Concomitant medicines that may worsen side effects may be adjusted.
7.1
Clinicians typically monitor growth and weight, especially in children and teens.
8.4
Qelbree can affect heart-rate and blood-pressure parameters in some patients.
5.2
Symptoms such as fainting, chest pain, or a sustained rapid heartbeat should be evaluated promptly by a clinician.
5.2
Unsupported Statements
Qelbree can cause sleep-related issues such as trouble sleeping.
Label discussions show sleep-related effects (somnolence, fatigue) but do not explicitly state trouble sleeping as a distinct symptom in the cited sections.
Qelbree can cause appetite changes.
Appetite changes are not explicitly supported as a labeled adverse effect in the cited sections.
Stopping treatment may be considered.
Discontinuation guidance exists in label sections, but the specific claim about stopping being considered is not reflected as a standalone recommendation in the cited claims evaluation.
Urgent medical care should be sought if Qelbree is associated with suicidal thoughts or behavior.
Label includes suicidality risk with monitoring; explicit directive to seek urgent care is not stated in the cited sections.
Urgent medical care should be sought if Qelbree is associated with severe mood or behavior changes (for example, unusual aggression, agitation, or worsening depression).
Label discusses mood/behavior changes and requires clinical assessment but not an explicit urgent-care directive.
Urgent medical care should be sought if Qelbree is associated with severe allergic reactions (such as swelling of the face/lips, trouble breathing, or widespread rash).
Hypersensitivity warnings exist, but an explicit urgent-care directive is not shown in the cited sections.
Mild but persistent side effects may require contacting the prescriber.
No explicit statement in the cited sections requiring contacting prescriber for mild persistent side effects.
Patients should not stop Qelbree suddenly without medical guidance.
Discontinuation/withdrawal guidance exists, but this exact directive is not captured in the cited claim evaluations.
Patients should report troubling effects promptly so the regimen can be adjusted safely.
While monitoring is described, this exact patient-facing directive is not explicitly stated in the cited sections.
If appetite drops significantly or weight loss becomes concerning, patients should talk with the prescriber.
An explicit statement of appetite-weight concerns prompting discussion is not directly cited in the labeled sections.
Staying hydrated can help manage GI symptoms.
No explicit hydration recommendation in the cited label sections.
Taking the medicine as directed can help manage GI symptoms.
No explicit GI symptom management guidance tied to adherence in the cited sections.
Reporting persistent GI symptoms can help manage them.
No explicit instruction to report persistent GI symptoms in the cited sections.
Severe or ongoing GI symptoms should be discussed with a clinician.
No explicit directive in the cited sections.
Discontinuation or abrupt stopping of Qelbree without medical guidance.
Discontinuation/withdrawal guidance exists, but the exact phrasing about abrupt stopping is not captured in the cited claim evaluations.
Contradictions
Important Omissions
Urgent medical care guidance for suicidality (suicidal thoughts or behaviors) explicitly stated in labeling; not clearly provided in the claims.
Importance:
High
Explicit urgent-care guidance for severe mood or behavior changes (e.g., unusual aggression, agitation, worsening depression).
Importance:
High
Hypersensitivity/allergic reaction warnings with explicit urgent evaluation guidance.
Importance:
High
Discontinuation or abrupt stopping of Qelbree without medical guidance.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The label contains important safety warnings (suicidality, mood/behavior changes, hypersensitivity) that are not fully captured in the claims; omissions could affect safety messaging.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omissions of high-risk warnings (suicidality, discontinuation guidance, and hypersensitivity) and explicit urgent-care guidance for severe mood/behavior changes.
Suggested Improvement
Incorporate explicit statements on suicidality risk and discontinuation guidance, and ensure urgent-care guidance for severe mood/behavior changes and hypersensitivity is clearly communicated in the user-facing outputs.